Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. The Lancet Oncology, Vol. 12(12), Nov 2011, p. 1101-1108.
Regan, M.M., et al.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70270-4/abstract?rss=yes
Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.
